Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Mucocutaneous Lymph Node Syndrome

ClinicalTrials.gov lists 62 trials for Mucocutaneous Lymph Node Syndrome or a narrower condition beneath it.

MeSH D009080 Cardiovascular Diseases C14 C15 C17 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 3 Phase 1/2 Phase 1/2 3 Phase 2 Phase 2 8 Phase 2/3 Phase 2/3 1 Phase 3 Phase 3 12 Phase 4 Phase 4 5 Not applicable Not applicable 6 Observational Observational 24 Phase 1 Phase 1 3 Phase 1/2 Phase 1/2 3 Phase 2 Phase 2 8 Phase 2/3 Phase 2/3 1 Phase 3 Phase 3 12 Phase 4 Phase 4 5 Not applicable Not applicable 6 Observational Observational 24

Trials per phase (log scale)

62 of the 62 trials are tagged with Mucocutaneous Lymph Node Syndrome itself; the rest are tagged with a narrower condition beneath it.

Get the Mucocutaneous Lymph Node Syndrome report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Mucocutaneous Lymph Node Syndrome trials start? (20)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 6

2002: 1 trials (Phase 3 1) 2004: 2 trials (Observational 1, Phase 1 1) 2005: 2 trials (Phase 3 1, Phase 1/2 1) 2006: 1 trials (Phase 2 1) 2007: 1 trials (Phase 2 1) 2009: 3 trials (Observational 1, Phase 3 1, Phase 2 1) 2010: 1 trials (Observational 1) 2011: 3 trials (Observational 2, Not applicable 1) 2012: 3 trials (Phase 4 1, Phase 3 1, Phase 1/2 1) 2013: 6 trials (Observational 2, Not applicable 1, Phase 3 2, Phase 2 1) 2014: 2 trials (Phase 3 1, Phase 1/2 1) 2016: 5 trials (Observational 1, Not applicable 2, Phase 2 2) 2017: 2 trials (Observational 1, Phase 3 1) 2019: 4 trials (Observational 2, Phase 4 1, Phase 1 1) 2020: 6 trials (Observational 3, Phase 3 2, Phase 1 1) 2021: 4 trials (Observational 2, Not applicable 1, Phase 2 1) 2023: 5 trials (Observational 4, Phase 3 1) 2024: 2 trials (Observational 1, Phase 4 1) 2025: 4 trials (Observational 1, Not applicable 1, Phase 4 2)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 4
2025 4
2024 2
2023 5
2021 4
2020 6
2019 4
2017 2
2016 5
2014 2

Showing 10 of 20 earlier years.

Start your 14-day trial Email me all 20 earlier years as a PDF

No forecast is made for this condition: it averages 3.0 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Mucocutaneous Lymph Node Syndrome trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 3
Phase 1/2 3
Phase 2 8
Phase 2/3 1
Phase 3 12
Phase 4 5
Not applicable 6
Observational 24

How many Mucocutaneous Lymph Node Syndrome trials are recruiting? (7)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 4
Recruiting 11
Enrolling by invitation 2
Active, not recruiting 1
Completed 28

Showing 5 of 7 statuses.

Start your 14-day trial Email me all 7 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Mucocutaneous Lymph Node Syndrome trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Green Cross Corporation 2
Lantheus Medical Imaging 2
Baxalta now part of Shire 1

Which drugs are being tested for Mucocutaneous Lymph Node Syndrome? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
INFLIXIMAB 6
Immunoglobulin 3
PREDNISOLONE 2
ATORVASTATIN 2

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
EC Aspirin 6
IVIG 6
Anakinra alone (stages 2b/3) 4
Globulin, Immune 3
Intravenous Immunoglobulins, Human 1

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Mucocutaneous Lymph Node Syndrome trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Continued Fever after treatment completion and crossover to other study treatment 31 1
Fever 23 2
Hospital readmission for retreatment 17 1
Fever following crossover treatment 11 1
Hemolytic Anemia 11 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Mucocutaneous Lymph Node Syndrome? (103)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
External Validation of a Machine Learning Model to Diagnose Kawasaki Disease. The Journal of pediatrics 2025 Yes
Intravenous Immunoglobulin Alone for Coronary Artery Lesion Treatment of Kawasaki Disease: A Randomized Clinical Trial. JAMA network open 2025 Yes
Etanercept with IVIg for acute Kawasaki disease: a long-term follow-up on the EATAK trial. Cardiology in the young 2023 Yes
Anakinra Treatment in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysms: A Phase I/IIa Trial. The Journal of pediatrics 2022 Yes
An Artificial Intelligence-guided signature reveals the shared host immune response in MIS-C and Kawasaki disease. Nature communications 2022 Yes

Showing 5 of 103 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (3)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Kawasaki disease Point prevalence Unknown Worldwide Not stated Exact
Kawasaki disease Point prevalence Unknown Worldwide Not stated Unspecified
Kawasaki disease Point prevalence Unknown Worldwide Not stated Exact

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Kawasaki disease 2331 Exact Orphadata Science knowledge files, Product 1
Kawasaki disease 2331 Exact Orphanet Rare Disease Ontology (ORDO)

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages